{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:03:44Z","timestamp":1785132224252,"version":"3.55.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejmech.2024.117172","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:03:23Z","timestamp":1734397403000},"page":"117172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Clinically approved representative small-molecule drugs for cardiopathy therapy"],"prefix":"10.1016","volume":"283","author":[{"given":"Shaowei","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117172_bib1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2024.117172_bib2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ecl.2022.02.005","article-title":"Assessment of cardiovascular disease risk: a 2022 update","volume":"51","author":"Goldsborough","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ejmech.2024.117172_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41569-024-00997-0","article-title":"Contemporary pharmacological treatment and management of heart failure","volume":"21","author":"Bozkurt","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejmech.2024.117172_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40256-023-00575-8","article-title":"Characteristics and trends in clinical trials of cardiovascular drugs in China from 2009 to 2021","volume":"23","author":"Hao","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103730","article-title":"Advancements in small molecule drug design: a structural perspective","volume":"28","author":"Wu","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2024.117172_bib6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2015.07.018","article-title":"Long-term use of cardiovascular drugs: challenges for research and for patient care","volume":"66","author":"Rossello","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2024.117172_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/156802609788340841","article-title":"New medicinal chemistry approaches for the treatment of cardiovascular disease","volume":"9","author":"Lee","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117172_bib8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41569-022-00717-6","article-title":"Repurposing drugs to treat cardiovascular disease in the era of precision medicine","volume":"19","author":"Abdelsayed","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejmech.2024.117172_bib9","series-title":"Acoramidis: A Promising Drug for Transthyretin Amyloid Cardiomyopathy","first-page":"1","author":"Bin Faheem","year":"2024"},{"key":"10.1016\/j.ejmech.2024.117172_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117172_bib11","first-page":"1346","article-title":"Acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Groothof","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117172_bib12","series-title":"Compounds and Compositions that Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions","author":"Graef","year":"2014"},{"key":"10.1016\/j.ejmech.2024.117172_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000687","article-title":"Landiolol for treating arrhythmias: a state-of-the-art review","author":"Ghallab","year":"2024","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.ejmech.2024.117172_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-018-0883-9","article-title":"Landiolol: a review in tachyarrhythmias","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib15","series-title":"Ono Pharmaceutical Co","article-title":"Preparation of phenylalkanoate esters as cardiovascular agents","author":"Iguchi","year":"1990"},{"key":"10.1016\/j.ejmech.2024.117172_bib16","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","article-title":"Mavacamten: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7622","article-title":"Mavacamten, a precision medicine for hypertrophic cardiomyopathy: from a motor protein to patients","volume":"9","author":"Nag","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2024.117172_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/ars.2017.7236","article-title":"Hypertrophic cardiomyopathy: a vicious cycle triggered by sarcomere mutations and secondary disease hits","volume":"31","author":"Wijnker","year":"2019","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.ejmech.2024.117172_bib19","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2024.117172_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s43044-023-00328-7","article-title":"Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials","volume":"75","author":"Rabiee Rad","year":"2023","journal-title":"Egypt Heart J"},{"key":"10.1016\/j.ejmech.2024.117172_bib21","series-title":"Pyrimidinonedione Compounds","author":"Oslob","year":"2017"},{"key":"10.1016\/j.ejmech.2024.117172_bib22","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","article-title":"Finerenone: first approval","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40119-022-00269-3","article-title":"Cardiovascular and renal outcomes with finerenone, a selective mineralocorticoid receptor antagonist","volume":"11","author":"Palanisamy","year":"2022","journal-title":"Cardiology and therapy"},{"key":"10.1016\/j.ejmech.2024.117172_bib24","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17512433.2022.2094770","article-title":"Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes","volume":"15","author":"Lerma","year":"2022","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117172_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1320603","article-title":"Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2024.117172_bib26","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.117172_bib27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40265-021-01496-z","article-title":"Vericiguat: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib28","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","article-title":"Clinical and research information on drug-induced liver injury","author":"Vericiguat","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117172_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40256-022-00538-5","article-title":"Vericiguat: a review in chronic heart failure with reduced ejection fraction","volume":"22","author":"Kang","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib30","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/cts.13677","article-title":"Vericiguat, a novel sGC stimulator: mechanism of action, clinical, and translational science","volume":"16","author":"Trujillo","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ejmech.2024.117172_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cardfail.2022.10.431","article-title":"Practical patient care considerations with use of Vericiguat after worsening heart failure events","volume":"29","author":"Rao","year":"2023","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ejmech.2024.117172_bib32","series-title":"Substituted 5-Fluoro-1h-Pyrazolopyridines and Their Use","author":"Follmann","year":"2015"},{"key":"10.1016\/j.ejmech.2024.117172_bib33","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1060028019888489","article-title":"Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy","volume":"54","author":"Park","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.117172_bib34","article-title":"2024 update in heart failure","author":"Beghini","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejmech.2024.117172_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of Tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ejmech.2024.117172_bib36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1517\/21678707.2013.841576","article-title":"Tafamidis for the treatment of transthyretin-associated familial amyloid polyneuropathy","volume":"1","author":"Schmidt","year":"2013","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib37","series-title":"Synthesis Method of Drug Tafamidis","author":"Yun","year":"2021"},{"key":"10.1016\/j.ejmech.2024.117172_bib38","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40265-019-01146-5","article-title":"Sotagliflozin: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib39","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s40265-019-01230-w","article-title":"Sotagliflozin: a review in type 1 diabetes","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib40","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2024.117172_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","article-title":"Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives","volume":"18","author":"Cefalo","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejmech.2024.117172_bib42","series-title":"Methods of Treating Diabetes","author":"De Paul","year":"2013"},{"key":"10.1016\/j.ejmech.2024.117172_bib43","first-page":"56","article-title":"Corlanor (ivabradine), first HCN channel blocker, FDA approved for the treatment of patients with heart failure","volume":"9","author":"Fala","year":"2016","journal-title":"American health & drug benefits"},{"key":"10.1016\/j.ejmech.2024.117172_bib44","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","article-title":"Clinical and research information on drug-induced liver injury","author":"Ivabradine","year":"2012"},{"issue":"Suppl 3","key":"10.1016\/j.ejmech.2024.117172_bib45","doi-asserted-by":"crossref","first-page":"S435","DOI":"10.1016\/j.ihj.2018.08.008","article-title":"Ivabradine: evidence and current role in cardiovascular diseases and other emerging indications","volume":"70","author":"Sathyamurthy","year":"2018","journal-title":"Indian Heart J."},{"key":"10.1016\/j.ejmech.2024.117172_bib46","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bja.2020.01.027","article-title":"Effect of ivabradine on major adverse cardiovascular events and mortality in critically ill patients: a systematic review and meta-analyses of randomised controlled trials with trial sequential analyses","volume":"124","author":"Chen","year":"2020","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.ejmech.2024.117172_bib47","series-title":"Process for the Synthesis of Ivabradine and Addition Salts Thereof with a Pharmaceutically Acceptable Acid","author":"Peglion","year":"2010"},{"key":"10.1016\/j.ejmech.2024.117172_bib48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1185\/03007995.2014.880050","article-title":"Cangrelor: an emerging therapeutic option for patients with coronary artery disease","volume":"30","author":"Kubica","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejmech.2024.117172_bib49","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","article-title":"Clinical and research information on drug-induced liver injury","author":"Cangrelor","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117172_bib50","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.jcin.2016.06.046","article-title":"Efficacy and safety of cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary intervention: the CHAMPION PHOENIX trial","volume":"9","author":"Abtan","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ejmech.2024.117172_bib51","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/erc.09.101","article-title":"Cangrelor: a review on its mechanism of action and clinical development","volume":"7","author":"Ferreiro","year":"2009","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.ejmech.2024.117172_bib52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijcard.2013.08.133","article-title":"Cangrelor infusion is associated with an increased risk for bleeding: meta-analysis of randomized trials","volume":"169","author":"Serebruany","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejmech.2024.117172_bib53","series-title":"6-N-(2-(Methylthio)ethyl)-2-((3,3,3-Trifluoropropyl)sulfo)-9H-purine, and Preparation Method and Application Thereof","author":"Yizhan","year":"2015"},{"key":"10.1016\/j.ejmech.2024.117172_bib54","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s40265-018-0937-z","article-title":"Empagliflozin: a review in type 2 diabetes","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib55","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117172_bib56","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11886-019-1219-4","article-title":"Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors","volume":"21","author":"Wojcik","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.ejmech.2024.117172_bib57","doi-asserted-by":"crossref","first-page":"F767","DOI":"10.1152\/ajprenal.00565.2018","article-title":"Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy","volume":"317","author":"Lee","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejmech.2024.117172_bib58","article-title":"Direct cardiac actions of sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejmech.2024.117172_bib59","series-title":"Process for the Preparation of Empagliflozin","author":"Kaushik","year":"2015"},{"key":"10.1016\/j.ejmech.2024.117172_bib60","first-page":"148","article-title":"Zontivity (vorapaxar), first-in-class PAR-1 antagonist, receives FDA approval for risk reduction of heart attack, stroke, and cardiovascular death","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.ejmech.2024.117172_bib61","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","article-title":"Clinical and research information on drug-induced liver injury","author":"Vorapaxar","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117172_bib62","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2146\/ajhp140758","article-title":"Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease","volume":"72","author":"Arif","year":"2015","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2024.117172_bib63","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001505","article-title":"Efficacy and safety of vorapaxar as approved for clinical use in the United States","volume":"4","author":"Magnani","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejmech.2024.117172_bib64","series-title":"Synthesis of Himbacine Analogs","author":"Thiruvengadam","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117172_bib65","first-page":"2493","article-title":"Dapagliflozin for the treatment of type 2 diabetes: a review of the literature","volume":"8","author":"Saeed","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2024.117172_bib66","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib67","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2024.117172_bib68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.117172_bib69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejmech.2024.117172_bib70","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1021\/ol300220p","article-title":"Stereoselective C-glycosylation reactions with arylzinc reagents","volume":"14","author":"Lemaire","year":"2012","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2024.117172_bib71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","article-title":"Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist","volume":"27","author":"Husted","year":"2009","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.ejmech.2024.117172_bib72","first-page":"91","article-title":"Ticagrelor, profiles drug subst excip","volume":"47","author":"Kabil","year":"2022","journal-title":"Relat Methodol"},{"key":"10.1016\/j.ejmech.2024.117172_bib73","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation","volume":"7","author":"Jj","year":"2009","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2024.117172_bib74","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s43440-021-00309-0","article-title":"A review of the effects of ticagrelor on adenosine concentration and its clinical significance","volume":"73","author":"Akkaif","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2024.117172_bib75","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.bmcl.2012.04.050","article-title":"Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents","volume":"22","author":"Zhang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.117172_bib76","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/cvr\/cvt006","article-title":"The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation","volume":"98","author":"Wettwer","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejmech.2024.117172_bib77","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1177\/1087057115601677","article-title":"Neuronal and cardiovascular potassium channels as therapeutic drug targets: promise and pitfalls","volume":"20","author":"Humphries","year":"2015","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.ejmech.2024.117172_bib78","series-title":"Clinical Handbook of Cardiac Electrophysiology","first-page":"249","article-title":"Anti-arrhythmic drugs","author":"Glover","year":"2016"},{"key":"10.1016\/j.ejmech.2024.117172_bib79","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/europace\/euz175","article-title":"Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis","volume":"21","author":"McIntyre","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.ejmech.2024.117172_bib80","series-title":"Process for Preparation of Aminocyclohexyl Ethers and Intermediate Products Used in the Process","author":"Gorin","year":"2013"},{"key":"10.1016\/j.ejmech.2024.117172_bib81","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/VHRM.S6185","article-title":"Dronedarone for atrial fibrillation: a new therapeutic agent","volume":"5","author":"Patel","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejmech.2024.117172_bib82","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","article-title":"Clinical and research information on drug-induced liver injury","author":"Dronedarone","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117172_bib83","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1093\/europace\/euaa426","article-title":"Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future","volume":"23","author":"Heijman","year":"2021","journal-title":"EP Europace"},{"key":"10.1016\/j.ejmech.2024.117172_bib84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4137\/CMC.S6677","article-title":"Safety and efficacy of dronedarone in the treatment of atrial fibrillation\/flutter","volume":"5","author":"Naccarelli","year":"2011","journal-title":"Clin. Med. Insights Cardiol."},{"key":"10.1016\/j.ejmech.2024.117172_bib85","first-page":"1764","article-title":"Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation","volume":"21","author":"Boriani","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.ejmech.2024.117172_bib86","series-title":"New Process for the Preparation of Dronedarone","author":"Friesz","year":"2011"},{"key":"10.1016\/j.ejmech.2024.117172_bib87","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/11204630-000000000-00000","article-title":"Tolvaptan","volume":"70","author":"Plosker","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib88","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","article-title":"Clinical and research information on drug-induced liver injury","author":"Tolvaptan","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117172_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","article-title":"Tolvaptan, an orally active vasopressin V2\u2010receptor antagonist\u2014pharmacology and clinical trials","volume":"25","author":"Miyazaki","year":"2007","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.ejmech.2024.117172_bib90","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2169\/internalmedicine.1697-18","article-title":"Hemodynamic and hormonal effects of tolvaptan for heart failure","volume":"58","author":"Kiuchi","year":"2019","journal-title":"Intern. Med."},{"key":"10.1016\/j.ejmech.2024.117172_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3810\/pgm.2012.03.2534","article-title":"Hyponatremia, heart failure, and the role of tolvaptan","volume":"124","author":"O'Connell","year":"2012","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ejmech.2024.117172_bib92","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0968-0896(99)00101-7","article-title":"3, 4, 5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist","volume":"7","author":"Kondo","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117172_bib93","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","article-title":"Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile","volume":"25","author":"Jakubowski","year":"2007","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.ejmech.2024.117172_bib94","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","article-title":"Clinical and research information on drug-induced liver injury","author":"Prasugrel","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117172_bib95","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1517\/14656566.9.16.2893","article-title":"Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development","volume":"9","author":"Angiolillo","year":"2008","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.117172_bib96","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1111\/j.1538-7836.2011.04450.x","article-title":"Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel","volume":"9","author":"Leadbeater","year":"2011","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2024.117172_bib97","series-title":"Process for the Preparation of Prasugrel and Several Novel Crystalline Forms of Prasugrel Hydrochloride","author":"Li","year":"2014"},{"key":"10.1016\/j.ejmech.2024.117172_bib98","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117172_bib99","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ejmech.2024.117172_bib100","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1177\/0091270007302952","article-title":"Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity","volume":"47","author":"Graff","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117172_bib101","series-title":"R., Method for Producing 5-Chloro-N-({5s)-2-Oxo-3-[4-(3-Oxo-4-Morpholinyl)-Phenyl]-1,3-Oxazolidin-5-Yl}-Methyl)-2-Thiophene Carboxamide","author":"Thomas","year":"2004"},{"key":"10.1016\/j.ejmech.2024.117172_bib102","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1039\/C4NP00064A","article-title":"Natural product and natural product derived drugs in clinical trials","volume":"31","author":"Butler","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2024.117172_bib103","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13019-022-01812-y","article-title":"Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach","volume":"17","author":"Hassan","year":"2022","journal-title":"J. Cardiothorac. Surg."},{"key":"10.1016\/j.ejmech.2024.117172_bib104","doi-asserted-by":"crossref","first-page":"54","DOI":"10.15420\/ecr.2018:8:2","article-title":"The newest generation of drug-eluting stents and beyond","volume":"13","author":"Lee","year":"2018","journal-title":"Eur. Cardiol."},{"key":"10.1016\/j.ejmech.2024.117172_bib105","series-title":"Method for Synthesizing Biolimus A9 and the like and Method for Improving Stability of the Same","author":"Guang-Zong","year":"2009"},{"key":"10.1016\/j.ejmech.2024.117172_bib106","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1592\/phco.2006.26.1.135","article-title":"Ranolazine, a novel agent for chronic stable angina","volume":"26","author":"Gaffney","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejmech.2024.117172_bib107","series-title":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)","article-title":"Clinical and research information on drug-induced liver injury","author":"Ranolazine","year":"2012"},{"key":"10.1016\/j.ejmech.2024.117172_bib108","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1054\/jcaf.2002.129232","article-title":"Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure","volume":"8","author":"Sabbah","year":"2002","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ejmech.2024.117172_bib109","series-title":"Crystalline and Amorphous Form of Ranolazine and the Process for Manufacturing Them","author":"Deshpande","year":"2006"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2024.117172_bib110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/A:1007735729121","article-title":"Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure","volume":"11","author":"Ruffolo","year":"1997","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejmech.2024.117172_bib111","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117172_bib112","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/14779072.5.1.21","article-title":"Carvedilol: use in chronic heart failure","volume":"5","author":"Doughty","year":"2007","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.ejmech.2024.117172_bib113","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/187152906779010746","article-title":"Carvedilol: just another Beta-blocker or a powerful cardioprotector?","volume":"6","author":"Carreira","year":"2006","journal-title":"Cardiovasc. Hematol. Disord.: Drug Targets"},{"key":"10.1016\/j.ejmech.2024.117172_bib114","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pbb.2008.10.005","article-title":"Neuroprotective effect of carvedilol, an adrenergic antagonist against colchicine induced cognitive impairment and oxidative damage in rat","volume":"92","author":"Kumar","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2024.117172_bib115","article-title":"Effects of carvedilol on blood pressure, blood sugar, and blood lipids in elderly patients with refractory hypertension","volume":"2022","author":"Zhang","year":"2022","journal-title":"Comput. Math. Methods Med."},{"key":"10.1016\/j.ejmech.2024.117172_bib116","series-title":"Process for Preparation of 1-(9h-Carbazol-4-Yloxy)-3-[[2-(2-Methoxyphenoxy) Ethyl] Amino]-2-Propanol","author":"Ashok","year":"2009"},{"key":"10.1016\/j.ejmech.2024.117172_bib117","doi-asserted-by":"crossref","first-page":"2a","DOI":"10.1016\/0002-9149(94)90268-2","article-title":"Unique pharmacologic properties of amlodipine","volume":"73","author":"Burges","year":"1994","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejmech.2024.117172_bib118","series-title":"Drugs and Lactation Database (LactMed\u00ae)","year":"2006"},{"key":"10.1016\/j.ejmech.2024.117172_bib119","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1476-5381.1993.tb13540.x","article-title":"The action of amlodipine on voltage-operated calcium channels in vascular smooth muscle","volume":"109","author":"Hughes","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117172_bib120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00005344-200101000-00008","article-title":"Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats","volume":"37","author":"Sandmann","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117172_bib121","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2165\/00003495-199141030-00009","article-title":"Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease","volume":"41","author":"Murdoch","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.117172_bib122","first-page":"32","article-title":"Synthesis of amlodipine using aza Diels-Alder reaction","volume":"23","author":"Kim","year":"2002","journal-title":"Bull. Kor. Chem. Soc."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:02:07Z","timestamp":1741287727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424010547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":122,"alternative-id":["S0223523424010547"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117172","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically approved representative small-molecule drugs for cardiopathy therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117172"}}